RECRUITING

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

Talk to us

Conditions

Attention Deficit DisorderAttention Deficit Disorder With Hyperactivity

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.

Official Title

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

Quick Facts

Study Start:2022-07-01
Study Completion:2025-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05354232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male and female outpatients 18-65 years of age
  2. 2. A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
  1. 1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
  2. 2. Active substance dependence (except for tobacco).
  3. 3. Pregnant or nursing females.
  4. 4. Inability to participate in testing procedures.
  5. 5. Premorbid neurological conditions (including neurovascular and neurodegenerative diseases such as traumatic brain injury, stroke, Parkinson's, AD and other dementias) and severe psychiatric disorders (bipolar disorder, schizophrenia).

Contacts and Locations

Study Contact

DNN Inbox
CONTACT
6177265348
mghdnn@mgh.harvard.edu

Principal Investigator

Joan Camprodon, MD, PHD, MPH
PRINCIPAL_INVESTIGATOR
MGB: Division of Neuropsychiatry and Neuromodulation

Study Locations (Sites)

Massachusetts General Hospital
Charlestown, Massachusetts, 02129
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Joan Camprodon, MD, PHD, MPH, PRINCIPAL_INVESTIGATOR, MGB: Division of Neuropsychiatry and Neuromodulation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-01
Study Completion Date2025-05-01

Study Record Updates

Study Start Date2022-07-01
Study Completion Date2025-05-01

Terms related to this study

Additional Relevant MeSH Terms

  • Attention Deficit Disorder
  • Attention Deficit Disorder With Hyperactivity